title: Treatment for hemophilia: recombinant versus plasma-derived coagulation factors - controversy and debate forever? An ethical medical challenge?
authors.affiliation: Department of Physiology, Biological Sciences School, Complutense University of Madrid, Cell Therapy and Regenerative Medicine Unit, La Paz University Hospital Health Research Institute-IdiPAZ, Madrid, 28040, Spain.
authors.forename: Antonio
authors.initials: A
authors.lastname: Liras
authors.forename: Rebecca
authors.initials: R
authors.lastname: García-Trenchard
mesh_terms: D001779:Blood Coagulation Factors / Q000009:adverse effects / Q000627:therapeutic use; D006467:Hemophilia A / Q000628:therapy*; D002836:Hemophilia B / Q000628:therapy*; D006801:Humans; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D001779:Blood Coagulation Factors; D011994:Recombinant Proteins